{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-26-084760","form_type":"8-K","ticker":"VYNE","cik":"0001566044","company_name":"VYNE Therapeutics Inc.","filed_at":"2026-07-18T00:41:06+00:00","discovered_at":"2026-07-20T10:05:00.260608+00:00","generated_at":"2026-07-20T10:05:27.394223+00:00","sec_items":["5.07"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"VYNE stockholders approve all proposals for merger with Yarrow Bioscience at special meeting","bullets":["Proposal 1 (issuance of shares >20% and change of control) approved: 15,915,017 for, 137,159 against.","Proposal 2 (reverse stock split 1:10-70) approved: 25,389,760 for, 550,694 against.","Proposal 3 (increase authorized shares from 150M to 300M) approved: 23,921,348 for, 2,013,526 against.","Proposal 4 (Yarrow 2026 Stock Incentive Plan) approved: 12,691,384 for, 3,358,164 against.","Proposal 5 (Yarrow 2026 Employee Stock Purchase Plan) approved: 13,131,018 for, 2,909,493 against."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-26-084760","json":"https://secwatch.observer/filing/0001104659-26-084760.json","markdown":"https://secwatch.observer/filing/0001104659-26-084760.md","text":"https://secwatch.observer/filing/0001104659-26-084760.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926084760/0001104659-26-084760-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1566044/000110465926084760/tm2620687d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-07-20T10:05:27.394223+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}